Literature DB >> 17662694

Additive effects of CpG ODN and R-848 as adjuvants on augmenting immune responses to HBsAg vaccination.

Rui Ma1, Jia-li Du, Jun Huang, Chang-you Wu.   

Abstract

In the present study, we tried to evaluate the ligands for Toll-like receptor 7 (TLR7) (R-848) and TLR 9 (CpG ODN) as adjuvants to augment the cellular and humoral immune responses as well as the generation of long-lasting immune memories following the vaccination with HBsAg in mice. The immune responses were assessed by enzyme-linked immunosorbent assay (ELISA), enzyme-linked immunospot (ELISPOT), and fluorescence-activated cell sorter (FACS) at the total and at the single-cell levels. Our results showed that CpG ODN or R-848 could enhance HBsAg-specific humoral and cellular immune responses following boosts. When R-848 in combination with CpG was used as adjuvants, the immune responses to HBsAg were further strengthened. Additional analysis demonstrated that the majority of the long-lasting HBsAg-specific T cells displayed effector memory phenotype. Taken together, our results imply that CpG ODN and R-848 may be the candidates as adjuvants for use in prophylactic and therapeutic hepatitis B vaccine.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17662694     DOI: 10.1016/j.bbrc.2007.07.028

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  15 in total

Review 1.  Immunogenomics and systems biology of vaccines.

Authors:  Luigi Buonaguro; Bali Pulendran
Journal:  Immunol Rev       Date:  2011-01       Impact factor: 12.988

2.  A Novel R848-Conjugated Inactivated Influenza Virus Vaccine Is Efficacious and Safe in a Neonate Nonhuman Primate Model.

Authors:  Beth C Holbrook; Jong R Kim; Lance K Blevins; Matthew J Jorgensen; Nancy D Kock; Ralph B D'Agostino; S Tyler Aycock; Mallinath B Hadimani; S Bruce King; Griffith D Parks; Martha A Alexander-Miller
Journal:  J Immunol       Date:  2016-06-08       Impact factor: 5.422

3.  An R848 adjuvanted influenza vaccine promotes early activation of B cells in the draining lymph nodes of non-human primate neonates.

Authors:  Beth C Holbrook; S Tyler Aycock; Emily Machiele; Elene Clemens; Danielle Gries; Matthew J Jorgensen; Mallinath B Hadimani; S Bruce King; Martha A Alexander-Miller
Journal:  Immunology       Date:  2017-10-24       Impact factor: 7.397

Review 4.  Role of innate immunity in the development of hepatocellular carcinoma.

Authors:  Rajagopal N Aravalli
Journal:  World J Gastroenterol       Date:  2013-11-21       Impact factor: 5.742

5.  The choice of linker for conjugating R848 to inactivated influenza virus determines the stimulatory capacity for innate immune cells.

Authors:  Marlena M Westcott; Elene A Clemens; Beth C Holbrook; S Bruce King; Martha A Alexander-Miller
Journal:  Vaccine       Date:  2018-02-21       Impact factor: 3.641

6.  Toll-like receptors as targets in chronic liver diseases.

Authors:  A Mencin; J Kluwe; R F Schwabe
Journal:  Gut       Date:  2009-05       Impact factor: 23.059

Review 7.  HIV and co-infections.

Authors:  Christina C Chang; Megan Crane; Jingling Zhou; Michael Mina; Jeffrey J Post; Barbara A Cameron; Andrew R Lloyd; Anthony Jaworowski; Martyn A French; Sharon R Lewin
Journal:  Immunol Rev       Date:  2013-07       Impact factor: 12.988

8.  Assessment of the effect of TLR7/8, TLR9 agonists and CD40 ligand on the transformation efficiency of Epstein-Barr virus in human B lymphocytes by limiting dilution assay.

Authors:  Vahid Younesi; Forough Golsaz Shirazi; Ali Memarian; Amir Amanzadeh; Mahmood Jeddi-Tehrani; Fazel Shokri
Journal:  Cytotechnology       Date:  2013-02-13       Impact factor: 2.058

Review 9.  Developmental biology of the innate immune response: implications for neonatal and infant vaccine development.

Authors:  Victoria Jane Philbin; Ofer Levy
Journal:  Pediatr Res       Date:  2009-05       Impact factor: 3.756

10.  Toll-like receptors in liver fibrosis: cellular crosstalk and mechanisms.

Authors:  Ling Yang; Ekihiro Seki
Journal:  Front Physiol       Date:  2012-05-22       Impact factor: 4.566

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.